NasdaqCM - Delayed Quote ? USD LakeShore Biopharma Co., Ltd (LSB) Follow Compare 2.1700 0.0000 (0.00%) As of November 6 at 4:00 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global leader in the discovery, development, manufacturing, and delivery of next-generation vaccines and therapeutic biologics for infectious diseases and cancer, today announced the initiation of its Biologics License Application (BLA) submission to the Drug Regulatory Authority of Pakistan (DRAP) for the conditional approval of its PIKA rabies vaccine for GlobeNewswire ? 2 hours ago LSB 0.00% LSBPW LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a written notice (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated October 21, 2024, informing the Company that it has PR Newswire ? 9 days ago LSB 0.00% LSBPW LakeShore Biopharma Advances with Rabies Vaccine Trial LakeShore Biopharma (LSB) has released an update. LakeShore Biopharma has received approval for a Phase III clinical trial in China to test a simplified four-dose regimen of its YSJA rabies vaccine, potentially enhancing patient adherence and reducing financial burdens. The trial aims to validate the vaccine’s safety and effectiveness compared to the current standard regimen, promising greater flexibility for patients and healthcare providers. This development could strengthen LakeShore Biopharm TipRanks ? 12 days ago LSB 0.00% LSBPW LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has been granted approval for a Phase III clinical trial (the "Trial") by the National Medical Products Administration (NMPA) in China to explore the immunogenicity and safety of a simplified four-d PR Newswire ? 13 days ago LSB 0.00% LSBPW LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it is providing financial guidance for the half year of its fiscal year of 2025 and reaffirming its financial guidance for the full year of its fiscal year 2025 ending on March 31, 2025 ("Fiscal Year 2 PR Newswire ? 30 days ago LSB 0.00% LSBPW LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on September 27, 2024 (Beijing Time) virtually via a Zoom video conference call. The EGM was called as part of the Company's efforts to rega PR Newswire ? last month LSB 0.00% LSBPW Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 10:00 a.m., Beijing time, on September 27, 2024, virtually via a Zoom video conference call, for the purpose of considering PR Newswire ? last month LSB 0.00% LSBPW LakeShore Biopharma Announces Leadership Transitions LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the board of directors of the Company (the "Board") has appointed Mr. Xu Wang as the Chief Executive Officer of the Company. He succeeds Mr. Dave Chenn and Dr. Hui Shao, who step down from the Company PR Newswire ? 2 months ago LSB 0.00% LSBPW LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal Year 2024"). PR Newswire ? 2 months ago LSB 0.00% LSBPW LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company received a shareholders' requisition dated June 14, 2024, issued by certain shareholders of the Company holding shares which carry in aggregate not less than 10% of all votes attaching to a PR Newswire ? 4 months ago LSB 0.00% LSBPW LakeShore Biopharma Insider Ups Holding By 3,083% During Year Viewing insider transactions for LakeShore Biopharma Co., Ltd's ( NASDAQ:LSB ) over the last year, we see that insiders... Simply Wall St. ? 4 months ago LSB 0.00% LSBPW LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? LakeShore Biopharma Co., Ltd ( NASDAQ:LSB ) is possibly approaching a major achievement in its business, so we would... Simply Wall St. ? 5 months ago LSB 0.00% LSBPW Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return LSB S&P 500 YTD -57.53% +24.92% 1-Year -57.86% +36.48% 3-Year -97.77% +26.84%
